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Abstract
Background: Recombinant human erythropoietin alpha (rHu-EPO) has been reported to protect the
liver of rats and mice from ischemia-reperfusion injury. However, direct protective effects of rHu-EPO on
hepatocytes and the responsible signalling pathways have not yet been described. The aim of the present
work was to study the protective effect of rHu-EPO on warm hypoxia-reoxygenation and cold-induced
injury to hepatocytes and the rHu-EPO-dependent signalling involved.
Methods: Loss of viability of isolated rat hepatocytes subjected to hypoxia/reoxygenation or incubated
at 4°C followed by rewarming was determined from released lactate dehydrogenase activity in the absence
and presence of rHu-EPO (0.2–100 U/ml). Apoptotic nuclear morphology was assessed by fluorescence
microscopy using the nuclear fluorophores H33342 and propidium iodide. Erythropoietin receptor
(EPOR), EPO and Bcl-2 mRNAs were quantified by real time PCR. Activation of JAK-2, STAT-3 and STAT-
5 in hepatocytes and rat livers perfused in situ was assessed by Western blotting.
Results: In contrast to previous in vivo studies on ischemia-reperfusion injury to the liver, rHu-EPO was
without any protective effect on hypoxic injury, hypoxia-reoxygenation injury and cold-induced apoptosis
to isolated cultured rat hepatocytes. EPOR mRNA was identified in these cells but specific detection of
the EPO receptor protein was not possible due to the lack of antibody specificity. Both, in the cultured
rat hepatocytes (10 U/ml for 15 minutes) and in the rat liver perfused in situ with rHu-EPO (8.9 U/ml for
15 minutes) no evidence for EPO-dependent signalling was found as indicated by missing effects of rHu-
EPO on phosphorylation of JAK-2, STAT-3 and STAT-5 and on the induction of Bcl-2 mRNA.
Conclusion:  Together, these results indicate the absence of any protective EPO signalling in rat
hepatocytes. This implies that the protection provided by rHu-EPO in vivo against ischemia-reperfusion
and other causes of liver injury is most likely indirect and does not result from a direct effect on
hepatocytes.
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Background
There is increasing evidence that erythropoietin alpha
(EPO) has cell- and tissue-protective properties independ-
ent of its hematopoietic activity [1-3]. In the liver, treat-
ment of rats and mice with recombinant human
erythropoietin alpha (rHu-EPO) significantly reduced
ischemia-reperfusion injury as indicated by decreases in
histopathological scores, release of liver enzymes, markers
of apoptosis, injurious intracellular signalling, and reac-
tive oxygen species formation [4-9]. In line with these
results rHu-EPO also promoted hepatic regeneration after
partial liver resection [10] and attenuated liver injury
associated with hemorrhagic shock [11].
The signalling pathways of rHu-EPO in non-erythroid
cells which are responsible for the protection provided by
EPO are still under investigation and are not yet com-
pletely resolved. As for erythroid progenitors the presence
and functionality of the EPO receptor (EPOR), a member
of the type I cytokine receptor family [12,13], appears to
be required. While it is known that in erythroid progeni-
tors the EPOR exists as a preformed homodimer, which
binds EPO, it has been suggested that in non-hematopoi-
etic tissues a heterodimer of the EPOR and the common
β-chain of the interleukin-3 receptor may mediate anti-
apoptotic effects of EPO [14]. Classical EPOR activation
depends on the recruitment of Janus tyrosine kinase 2
(JAK-2) and subsequent activation of signal transducer
and activator of transcription 5 (STAT-5) [15]. However, a
variety of additional signal transduction pathways have
been proposed. In this context, signalling via signal trans-
ducer and activator of transcription 3 (STAT-3) is consid-
ered to be involved in transducing EPO-dependent cell
protection in non-erythroid tissues [16-18]. B-cell lym-
phoma 2 (Bcl-2) is among the target genes that confer the
anti-apoptotic action of EPO in hematopoietic progenitor
cells [19].
Here we report the unexpected finding that rHu-EPO did
not protect primary cultured rat hepatocytes against
hypoxic injury, hypoxia-reoxygenation injury and against
cold-induced, free radical-mediated apoptosis. Subse-
quent studies with cultured hepatocytes and the rat liver
perfused in situ strongly indicate the absence of EPO sig-
nalling in rat hepatocytes to account for the missing pro-
tection by the cytokine.
Methods
Materials
Recombinant human erythropoietin alpha (rHu-EPO;
stocks: commercial ERYPO®  Product Line, 10,000 or
40,000 U/ml; 5.0 mg glycine/ml, preservative free without
albumin and citrate) was kindly provided by Janssen-
Cilag (Neuss, Germany). Primers for real-time polymerase
chain reactions (PCRs) were obtained from Invitrogen
(Karlsruhe, Germany), the RC DC Protein Assay® was pur-
chased from Bio-Rad (Munich, Germany), and avian mye-
loblastosis virus reverse transcriptase from Promega
(Heidelberg, Germany). Fetal calf serum, 2,2'-dipyridyl,
Leibovitz L-15 medium, and Ponceau S came from Sigma-
Aldrich (Taufkirchen, Germany). The fluorescent dye
SYBR Green® (for real time PCR) was obtained from Euro-
gentec (Verviers, Belgium). The Primer Express software
and the Gene Amp 5700 Sequence Detection System were
obtained from Applied Biosystems (Weiterstadt, Ger-
many). For the determination of total and phosphor-
ylated STAT-3 and STAT- 5 and phosphorylated JAK-2 the
PhosphoPlus®Stat3 (Tyr705), the PhosphoPlus®Stat5
(Tyr694) and the Phospho-Jak2 (Tyr1007/1008) anti-
body kits from Cell Signalling Technology® (Frankfurt,
Germany) were used, respectively. The NE-PER® nuclear
and cytoplasmic extraction kit was purchased from Pierce
Biotechnology (Schwerte, Germany), EPOR antibodies C-
20 (sc695) were from Santa Cruz (Heidelberg, Germany)
and gas mixtures from Messer Griesheim (Krefeld, Ger-
many).
Animals
Male Wistar rats (300–350 g) were obtained from the Zen-
trales Tierlaboratorium (Universitätsklinikum Essen).
Animals were kept under standard conditions with free
access to food and water. All animals received humane
care in compliance with the institutional guidelines.
Perfusion of the rat liver in situ
Rat livers were perfused as previously described [20] with
some modifications. Briefly, subsequent to ketamine/
xylazine anaesthesia (80 mg and 6 mg, respectively, per kg
body weight via intraperitoneal injection) animals under-
went median laparotomy. Then the portal vein was can-
nulated and a peristaltic pump used to start perfusion of
the liver at 30 ml/min with warm (37°) modified Krebs-
Henseleit (KH) buffer (115 mM NaCl, 25 mM NaHCO3,
5.9 mM KCl, 1.2 mM MgCl2, 1.2 mM NaH2PO4, 1.2 mM
Na2SO4, 2.5 mM CaCl2, 20 mM HEPES, pH 7.4) that had
been equilibrated with 95% O2/5% CO2 (carbogen); to
avoid congestion of the liver, the Vena cava inferior was cut
distally from the Venae renalis immediately after perfusion
had started. Subsequent to thoracotomy the perfusate was
drained through a second cannula that had been placed
within the suprahepatic Vena cava inferior via the right
atrium and the infrahepatic Vena cava inferior was ligated
between the liver and the Venae renalis to avoid loss of the
perfusate. After a short (2–3 minutes) perfusion period
that was required to completely remove the blood within
the liver, rHu-EPO was added to the reservoir bottle and
rapidly mixed with the KH buffer to gain 8.9 U/ml; in con-
trols no rHu-EPO was added. Then non-recirculating in
situ liver perfusion was continued for further 15 minutes.
Afterwards, the complete liver was removed and rapidlyBMC Gastroenterology 2009, 9:26 http://www.biomedcentral.com/1471-230X/9/26
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frozen in liquid nitrogen until tissue processing for ana-
lytic assays.
Isolation of the hepatocytes, culture and pre-treatment 
with rHu-EPO
Hepatocytes were isolated from male Wistar rats, seeded
onto collagen-coated culture flasks or glass coverslips and
cultured as described previously [21]. Experiments were
started 20–22 hours after isolation of the cells. Hepato-
cytes were pre-incubated with rHu-EPO (0.2–100 U/ml)
for 15 minutes, 2, 3, 18 or 20 hours (over night, subse-
quent to their isolation) in L-15 medium at 74% N2/21%
O2/5% CO2 (37°C, humidified atmosphere).
Culture of UT-7 cells with rHu-EPO
UT-7 cells, an erythropoietin-responsive hematopoietic
cell line [22], which was generously provided by P.
Mayeux (INSERM 152, Hopital Cochin, Paris, France),
served as a positive control for EPOR signalling. UT-7 cells
were grown in suspension in RPMI 1640 cell culture
medium from BioWitthaker (Verviers, Belgium) supple-
mented with 10% fetal bovine serum from Biochrom
(Berlin, Germany) and 1 U rHu-EPO/ml; cells were split-
ted twice/week. For experiments, cells were used at a den-
sity of 106 cells/ml and kept in medium without rHu-EPO
for 1 hour before the start of the experiment.
Induction of hypoxia/reoxygenation in cultured 
hepatocytes
At the beginning of the experiments, hepatocytes were
washed three times with Hanks' balanced salt solution
(137.0 mM NaCl, 5.4 mM KCl, 1.0 mM CaCl2, 0.5 mM
MgCl2, 0.4 mM KH2PO4, 0.4 mM MgSO4, 0.3 mM
Na2HPO4, 25.0 mM HEPES, pH 7.4) and then covered
with KH buffer at 37°C. Normoxic incubations (controls)
were performed in a humidified atmosphere of 74% N2/
21% O2/5% CO2. Hypoxic conditions were established by
saturating the incubation solution with 95% N2/5% CO2
before adding it to the cells, followed by gentle flushing of
the culture flasks with the gas mixture through cannulae
piercing the rubber stoppers of the flasks, as described pre-
viously [21,23,24]. After locking the flasks, cells were
incubated for 5–6.5 hours within an incubator at 37°C.
The flasks were again flushed with the respective gas mix-
tures each time a sample was taken. RHu-EPO (0.2–100
U/ml) was added to the KH buffer just prior to its addition
to the cells. Some experiments were performed with rHu-
EPO that had been heat-inactivated by boiling for 30 min-
utes. Where indicated, glycine (66 μM, 0.66 mM or 10
mM) was added to the cells prior to the start of the
hypoxic treatment. Reoxygenation of the cells was per-
formed after different hypoxic periods by gassing the
flasks with 74% N2/21% O2/5% CO2 for 2 minutes fol-
lowed by an incubation in this atmosphere within an
incubator at 37°C. Moderate hypoxia was achieved by
placing the culture dishes in an incubator with 1% or 3%
O2 (5% CO2 and N2 as balance) for the indicated time
periods.
For fluorescence microscopy, 6-well cell culture plates,
containing collagen-coated coverslips with adherent
hepatocytes that had been pre-treated or not with rHu-
EPO for 20 hours, washed and supplied with KH buffer ±
rHu-EPO (10 or 100 U/ml), were placed in air-tight ves-
sels that were then flushed for 10 minutes either with 74%
N2/21% O2/5% CO2 or 95% N2/5% CO2. After locking
the vessels, cells were incubated for 2–4 hours at 37°C;
note that hepatocytes died more slowly in the hypoxic ves-
sel than in culture flasks (see above), as pre-equilibration
of the medium with 95% N2/5% CO2 was not possible.
Afterwards, the buffer was removed and the cells were
incubated for 24 hours in L-15 medium (37°C) again
with or without rHu-EPO at 74% N2/21% O2/5% CO2.
Induction of cold-induced apoptosis
Hypothermic injury was induced according to refs.
[25,26]. Cultured hepatocytes were washed with Hanks'
balanced salt solution and cells covered with University of
Wisconsin solution or L-15 medium with or without rHu-
EPO (2, 10, 50 or 100 U/ml; medium supplemented as
described previously [26]) at room temperature. Incuba-
tions in cell culture medium were performed in air-tight
vessels which were flushed with 74% N2/21% O2/5%
CO2, cells in University of Wisconsin solution were
exposed to room air; cells were incubated at 4°C for 24
hours. In some experiments, the iron chelator 2,2'-dipyri-
dyl (100 μM) was added at the beginning of the cold incu-
bation as a positive control for protection from cold-
induced injury in University of Wisconsin solution and, in
other experiments, in order to assess an effect of rHu-EPO
to the weaker iron-independent component of cold-
induced apoptosis to hepatocytes in L-15 medium
[27,28]. Increases in the hepatocyte chelatable iron pool
were provoked in cell culture medium at 74% N2/21%
O2/5% CO2 by the addition of the membrane-permeable
Fe(III)/8-hydroxyquinoline complex ([29]; prepared as
described previously [30]).
Assessment of cellular and nuclear alterations (apoptotic 
vs. necrotic cell death)
Hepatocyte morphology after various periods of hypoxia
and reoxygenation, respectively, was assessed by phase
contrast microscopy. Nuclear morphology was assessed
by fluorescence microscopy according to ref. [26]. Twenty
fields of vision (original magnification: × 400) à 15–30
hepatocytes were visually evaluated (blinded) per condi-
tion and experiment.
Loss of cell viability was assessed by the determination of
extracellular, i.e. released, lactate dehydrogenase (LDH)BMC Gastroenterology 2009, 9:26 http://www.biomedcentral.com/1471-230X/9/26
Page 4 of 12
(page number not for citation purposes)
activity; released LDH activity is given as percentage of
total LDH activity [26].
Detection and quantification of EPOR, EPO and Bcl-2 
mRNA
Isolation of total RNA from cultured hepatocytes and per-
fused liver, reverse transcription into cDNA and real-time
PCR were performed as described [31]. Primers for real-
time PCR were designed to yield amplicon sizes of 150 bp,
annealing temperature of 60°C and CG content of about
60%. Primers for real-time PCRs were: EPOR upstream
EPOR1 5'-ccg gga tgg gct tca act ac-3' and downstream
EPOR2 5'-tcc agt ggc aca aaa ctc gac-3' spanning nucle-
otides 291 – 441 or for detection of full length EPOR
mRNA EPOR3 5'-ggg cta cat cat gga cca act c-3'and EPOR4
5'-ggc tgg agt cct agg agc agg cc-3' spanning nucleotides 71
– 1616 of rat EPO receptor sequence NM_017002.2.
Primers for EPO mRNA were upstream 5'-ggt cac ctg tcc cct
ctc ct -3' and downstream 5'-ctg gag tgt cca tgg gac ag-3' and
for Bcl-2 upstream 5'-gga cgc gaa gtg cta ttg g-3' and down-
stream 5'-ccg aac tca aag aag gcc ac-3', respectively. The
identities of the amplification products for EPOR were
verified by sequencing (SEQLAB; Göttingen, Germany).
Determination of activated JAK-2, STAT-3 and STAT-5
Cultured rat hepatocytes and UT-7 cells were treated with
10 U rHu-EPO/ml for 15 minutes and rat livers perfused
in situ with 8.9 U/ml rHu-EPO (for 15 minutes). Cellular
extracts were prepared using the NE-PER® nuclear and
cytoplasmic extraction kit and used for Western blotting
to detect nuclear phosphorylated and thus activated JAK-
2 (pJAK-2), STAT-3 (pSTAT-3) and STAT-5 (pSTAT-5)
exactly as described in the protocol from Cell Signalling
Technology®. As positive controls, extracts from the EPO-
responsive cell line UT-7 were used. Western blotting and
detection were performed as described in Frede et al. [32].
Statistics
All experiments were performed in duplicate and repeated
at least 3 times. Traces and blots shown in the figures are
representative for all the corresponding experiments car-
ried out. Data are expressed as mean values ± or + SD.
Data obtained from two groups were compared by means
of Student's t test (matched values, two-tailed, paired) and
comparisons among multiple groups were performed
using an analysis of variance (ANOVA). A p-value of <
0.05 was considered significant.
Results
Effect of rHu-EPO on hypoxia-reoxygenation injury to 
cultured rat hepatocytes
For the induction of hepatocellular injury, occurring
either already during the hypoxic period or upon reoxy-
genation oxygen partial pressures (pO2) below 0.3 mm
Hg, i.e. deep hypoxia (anoxia), is required [33]. The mech-
anism of injury in the hypoxic period (like the mechanism
of hepatocellular injury in the ischemic liver) is consid-
ered to be necrotic [34,35]. Upon reoxygenation, the
mode of hepatocellular injury is highly variable ranging
from necrotic to apoptotic cell death (again similar to the
situation in the reperfused liver [34,35]).
When cultured rat hepatocytes were incubated under
hypoxic conditions, 70 ± 2% of the cells lost their viability
during 5 hours of incubation (Figure 1). Glycine (10 mM)
largely protected the cells, in line with previous reports
[23,24,36-38]. In contrast to glycine, rHu-EPO (≥ 10 U/
ml; 2 or 20 hours pre-incubation) only slightly attenuated
Effect of rHu-EPO on the hypoxic injury to cultured hepato- cytes Figure 1
Effect of rHu-EPO on the hypoxic injury to cultured 
hepatocytes. Cultured rat hepatocytes were pre-incubated 
in the presence or absence of rHu-EPO (100 U/ml) in L-15 
medium (37°C) for 20 hours at normoxia (74% N2/21% O2/
5% CO2). Then the cells were incubated in modified Krebs-
Henseleit (KH) buffer (37°C) for 5 hours, again with or with-
out rHu-EPO, under deep hypoxia (gassing with 95% N2/5% 
CO2; closed symbols) or normoxic conditions (open sym-
bol). In some experiments glycine (10 mM) was added before 
starting the hypoxic treatment; other experiments were per-
formed using heat-inactivated (30 minutes at 100°C) rHu-
EPO. Cell injury was determined by the release of cytosolic 
lactate dehydrogenase (LDH). Values shown represent 
means ± S.D. of 4 independent experiments. *p < 0.05 vs. 
respective incubations at hypoxia with no addition; glycine 
(10 mM) provided significant protection (p < 0.05) vs. 
respective incubations at hypoxia (not indicated). Closed 
squares: hypoxia, no addition; closed circles: hypoxia, 100 U 
rHu-EPO/ml; closed triangles: hypoxia, 100 U heat-inacti-
vated rHu-EPO/ml; closed diamonds: hypoxia, 10 mM glycine; 
open squares: normoxia, no addition.BMC Gastroenterology 2009, 9:26 http://www.biomedcentral.com/1471-230X/9/26
Page 5 of 12
(page number not for citation purposes)
hepatocyte hypoxic death (Figure 1; data shown for 100 U
rHu-EPO/ml and 20 hours pre-incubation). Furthermore,
based on experiments with heat-inactivated rHu-EPO and
glycine, this effect could be fully explained by the presence
of contaminant glycine (0.66 mM in samples with 100 U
rHu-EPO/ml) used by the manufacturer to stabilize the
rHu-EPO stock solution. Hepatocytes appeared to be pro-
tected even more effectively in experiments with heat-
inactivated rHu-EPO than in experiments with the intact
hormone (Figure 1), suggesting a moderate negative effect
of the latter. At normoxia, however, pre-incubation of the
cells with rHu-EPO (0.2–100 U/ml for up to 20 hours) in
L-15 medium and incubation in KH buffer had no effect
at all on cell viability (data not shown; n = 5).
Subsequent to 30 or 60 minutes of hypoxia (not shown; n
= 4 each), reoxygenation only slightly increased the loss of
cell viability. Reoxygenation injury became more obvious
when the hypoxic period was prolonged to 2 hours (Fig-
ure 2). As in experiments with permanent hypoxia, rHu-
EPO (≥ 10 U/ml; 2 or 20 hours pre-incubation) provided
moderate protection (data shown for 10 U rHu-EPO/ml
and 20 hours pre-incubation). Again, this protective effect
was most likely mediated by glycine, as disclosed in con-
trols with the amino acid and the heat-inactivated hor-
mone, respectively.
Since the onset of cell injury induced by hypoxia and
developing during reoxygenation may be a late event, the
effect of rHu-EPO on reoxygenation injury was studied 24
hours after a sublethal hypoxic period (Figure 3). Double
staining with the nuclear fluorophores H33342 and pro-
pidium iodide revealed that under these conditions reox-
ygenation predominantly resulted in hepatocyte
apoptotic alterations. Nuclei were condensed and/or ruf-
fled and condensation of chromatin was detectable in
cells that still excluded propidium iodide. However, chro-
matin margination and nuclear fragmentation was hardly
observed. The cells with primarily apoptotic nuclei finally
took up propidium iodide, suggesting the occurrence of
secondary necrosis. RHu-EPO (10 and 100 U/ml; 20
hours pre-incubation and for 24 hours after hypoxia) did
not diminish these apoptotic alterations but even slightly
enhanced them (not significantly) as compared with the
heat-inactivated protein, which had no effect.
Effect of rHu-EPO on cold-induced apoptosis of cultured 
rat hepatocytes
In former studies we have demonstrated that the incuba-
tion of cultured rat hepatocytes at 4°C leads to an
increased cellular "chelatable iron pool" (i.e. cellular iron
ions accessible to iron chelators) which later mediates the
opening of the mitochondrial permeability transition
pore eventually triggering apoptotic cell death [25,28,39].
This injurious mechanism to hepatocytes is likely to play
a role under the conditions of liver transplantation.
Initially, experiments were performed in University of
Wisconsin solution, as cold incubation in this solution is
known to result in hepatocyte cold-induced injury that
solely depends on the iron-dependent mechanism
described above [25]. When cultured hepatocytes were
incubated in University of Wisconsin solution at 4°C,
about 90% of the cells died within 24 hours cold incuba-
tion/3 hours rewarming (Figure 4A). The bidentate iron
chelator 2,2'-dipyridyl, forming a redox-inactive complex
with cellular chelatable iron, almost completely pre-
vented loss of cell viability. In contrast, rHu-EPO (2, 10,
50 or 100 U/ml; 2 or 18 hours pre-incubation) had no
effect on the course of cell death (Figure 4A; data shown
for 10 and 100 U rHu-EPO/ml and 18 hours pre-incuba-
Effect of rHu-EPO on the reoxygenation injury to cultured  hepatocytes Figure 2
Effect of rHu-EPO on the reoxygenation injury to cul-
tured hepatocytes. Cultured rat hepatocytes were pre-
incubated in the presence or absence of rHu-EPO (10 U/ml) 
in L-15 medium (37°C) for 20 hours at normoxia (74% N2/
21% O2/5% CO2). Then the cells were incubated in modified 
Krebs-Henseleit (KH) buffer, again with or without rHu-
EPO, under deep hypoxia (for 120 minutes) followed by nor-
moxia (37°C). In some experiments glycine (66 μM) was 
added before starting the hypoxic treatment; other experi-
ments were performed using heat-inactivated (30 minutes at 
100°C; heat-inactiv.) rHu-EPO. Cell injury was determined 
by the release of cytosolic lactate dehydrogenase (LDH). Val-
ues shown represent means ± S.D. of 4 independent experi-
ments. *p < 0.05 (66 μM glycine and 10 U EPO/ml, heat-
inactiv.) vs. respective incubations at hypoxia with no addi-
tion. Closed squares: hypoxia/reoxygenation, no addition; 
closed circles: hypoxia/reoxygenation, 10 U rHu-EPO/ml; 
closed triangles: hypoxia/reoxygenation, 10 U heat-inacti-
vated rHu-EPO/ml; closed diamonds: hypoxia/reoxygenation, 
66 μM glycine.BMC Gastroenterology 2009, 9:26 http://www.biomedcentral.com/1471-230X/9/26
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Effect of rHu-EPO on the changes of nuclear morphology of  cultured hepatocytes as induced by hypoxia/reoxygenation Figure 3
Effect of rHu-EPO on the changes of nuclear mor-
phology of cultured hepatocytes as induced by 
hypoxia/reoxygenation. Cultured rat hepatocytes on col-
lagen-coated glass coverslips in 6-well cell culture plates 
were pre-treated or not with rHu-EPO (10 or 100 U/ml) in 
L-15 medium (37°C) for 20 hours. Then the cells were sup-
plied with KH buffer with or without rHu-EPO (10 or 100 U/
ml) and placed in air-tight vessels that were flushed for 10 
minutes either with 74% N2/21% O2/5% CO2 or 95% N2/5% 
CO2. Cells were then incubated for 3 hours at 37°C. After-
wards, the buffer was removed and the cells were incubated 
for 24 hours in L-15 medium (37°C) again with or without 
rHu-EPO at 74% N2/21% O2/5% CO2. Nuclear morphology 
was assessed by fluorescence microscopy (λexc = 365 ± 12.5 
nm, λem ≥ 515 nm; original magnification × 400) after double-
staining of the cells with the membrane-permeable DNA-
binding fluorochrome H33342 (1 μg/ml; green fluorescence) 
and the DNA-binding fluorochrome propidium iodide (5 μg/
ml), that is impermeable to the intact plasma membrane but 
stains nuclei of necrotic and late apoptotic cells (red fluores-
cence). Twenty fields of vision à 15–30 hepatocytes were vis-
ually evaluated (blinded) per experiment. In (A) the effect of 
hypoxia/reoxygenation on the nuclear morphology is shown; 
bar represents 20 μm. (B) shows the effect of rHu-EPO on 
nuclear apoptotic alterations occurring after hypoxia/reoxy-
genation (hypox./reox.) in % of the normoxic controls. The 
microfluorographs shown are representative for three 
experiments with hepatocytes from different animals; bars 
represent means + S.D. of 3 independent experiments. 
Nuclear apoptotic alterations were defined as nuclear con-
densation, ruffling and/or fragmentation (white arrows) that 
had already occurred in cells that did not take up propidium 
iodide.
Effect of rHu-EPO on cold-induced apoptosis of cultured rat  hepatocytes Figure 4
Effect of rHu-EPO on cold-induced apoptosis of cul-
tured rat hepatocytes. (A) rat hepatocytes were pre-incu-
bated in the presence or absence of rHu-EPO (10 or 100 U/
ml) in L-15 medium for 18 hours at 37°C (74% N2/21% O2/
5% CO2). Cells were then exposed to hypothermia (4°C) in 
University of Wisconsin solution with or without rHu-EPO. 
To prevent iron-dependent cold-induced apoptosis, the iron 
chelator 2,2'-dipyridyl (2,2'-DPD, 100 μM) was added prior 
to cold incubation. In (B), the effect of rHu-EPO on the iron-
independent component of cold-induced apoptosis is shown. 
Cells were pre-incubated with rHu-EPO for 18 hours and 
then exposed to hypothermia in L-15 medium with or with-
out rHu-EPO and/or 2,2'-DPD (100 μM). The occurrence of 
cell injury (including late apoptosis) was assessed by the 
release of lactate dehydrogenase (LDH). Values represent 
means ± S.D. of 3 independent experiments. (A) Open 
squares: hypothermia/rewarming, no addition; closed circles: 
hypothermia/rewarming, 100 U rHu-EPO/ml; closed squares: 
hypothermia/rewarming, 10 U rHu-EPO/ml; open circles: 
hypothermia/rewarming, 100 μM 2,2'-DPD. (B) Open 
squares: hypothermia/rewarming, no addition; open circles: 
hypothermia/rewarming, 100 μM 2,2'-DPD; closed circles: 
hypothermia/rewarming, 100 μM 2,2'-DPD and 10 U rHu-
EPO/ml; closed triangles: hypothermia/rewarming, 100 μM 
2,2'-DPD and 100 U rHu-EPO/ml.BMC Gastroenterology 2009, 9:26 http://www.biomedcentral.com/1471-230X/9/26
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tion). As to be expected from these results, rHu-EPO had
also no protective effect on cell injury induced by redox-
active labile iron ions (15 μM Fe(III)-bis(8-hydroxyquin-
oline); data not shown, n = 3), known to induce a mito-
chondrial permeability transition and subsequent
apoptotic cell death in hepatocytes [40].
As cultured rat hepatocytes are known to die from both an
iron-dependent (see above) and a weaker iron-independ-
ent pathway when the cells are incubated in cold L-15
medium [27,28], we studied whether rHu-EPO prevents
the iron-independent component of cold-induced cell
injury. The iron chelator 2,2'-dipyridyl strongly decreased
loss of cell viability (Figure 4B). RHu-EPO, however, did
not decrease the remaining iron-independent component
of the cold-induced injury.
Detection of EPOR mRNA in perfused rat livers and 
cultured rat hepatocytes. Effects of rHu-EPO
Primers designed to span the whole cDNA derived from
the transcript revealed full length EPOR transcripts in cul-
tured hepatocytes and perfused livers. In addition, prim-
ers spanning the membrane proximal and membrane
spanning part of the EPOR confirmed expression of EPOR
mRNA in all our samples from livers and hepatocytes (Fig-
ure 5). Qualitative RT-PCR revealed a single amplification
product of hepatocyte and liver EPOR mRNA (Figure 5A)
which was identical in size with our positive EPOR con-
trol (UT-7 cells). Levels of EPOR expression did not
change during culture of hepatocytes when compared
with freshly isolated liver tissue but were lower than in
UT-7 cells (Figure 5A). When the mRNA was quantified by
real time RT-PCR we found that hypoxia (mild hypoxia,
3% O2) decreased EPOR mRNA of hepatocytes to about
60% of the values under normoxia within 4 hours of incu-
bation (Figure 5B). Since quantitative real time RT-PCR
revealed a more than two-fold increase of EPO mRNA
under hypoxia as compared to normoxic controls a gen-
eral decrease of gene expression does not account for the
lower EPOR mRNA levels under hypoxia. The addition of
rHu-EPO (10 or 100 U/ml; 2 or 18 hours pre-incubation)
did not affect EPOR mRNA levels under normoxic and
moderate hypoxic conditions (4, 12 or 24 hours at 3% O2;
data not shown; n = 3 – 4).
To verify the presence of the EPOR protein, Western blot
analysis was carried out. Unfortunately, however, a spe-
cific antibody to EPOR is not available at present. Using a
polyclonal antibody for the EPOR, we detected several
bands of about the predicted size but could not reliably
identify the EPOR protein, a results which is in full agree-
ment with Elliott et al. [41] who questioned the specificity
of the EPOR antibodies used. All bands around the pre-
dicted size of EPOR showed no change in their intensity
upon treatment with rHu-EPO (10 or 100 U/ml; 2 or 18
hours pre-incubation; data not shown; n = 3).
Activation of EPOR signalling in UT-7 cells but not in 
hepatocytes and perfused livers
The mRNA of the classical EPOR downstream target, the
anti-apoptotic Bcl-2 gene, was detected in cultured hepa-
tocytes. However, Bcl-2 mRNA was not induced by rHu-
EPO treatment (10 U/ml for 30 h; Figure 6). In fact, Bcl-2
mRNA strongly decreased under hypoxia and rHu-EPO
was not able to overcome this effect. Even much higher
doses of EPO added for 24 h had no effect on Bcl-2 expres-
sion (Table 1).
Oxygen dependence of hepatocyte mRNA expression of  EPOR and EPO Figure 5
Oxygen dependence of hepatocyte mRNA expres-
sion of EPOR and EPO. (A) qualitative PCR of EPOR 
cDNA reverse transcribed from mRNA. Subsequent to their 
isolation hepatocytes were cultured in L-15 medium (37°C) 
for 20–22 hours at normoxia (74% N2/21% O2/5% CO2). 
Total RNA was extracted from the hepatocytes or from 
fresh tissue of perfused livers. Using primer EPOR1 and 
EPOR2 (see Methods), a single PCR product (arrow) was 
obtained which was sequenced and proved to be from the 
EPOR. For comparison, data from UT-7 cells ate shown. Lev-
els of EPOR mRNA in liver tissue were around 152 ± 27 pg/
μl RNA. (B) Real time PCR quantitation of EPOR and EPO 
mRNA. Hepatocytes were incubated for further 4 hours 
under normoxia or hypoxia (3% O2). Afterwards total RNA 
was extracted as in (A). 5 to 6 samples per treatment were 
analysed. Shown are mean values + S.D. *p < 0.05 vs. respec-
tive incubations at normoxia; MWM: molecular weight 
marker.BMC Gastroenterology 2009, 9:26 http://www.biomedcentral.com/1471-230X/9/26
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To more directly study EPOR-induced intracellular signal-
ling, EPO-responsive activation of JAK-2, STAT-3 and
STAT-5 was determined in perfused livers and cultured
hepatocytes. Rat livers were perfused in situ with KH buffer
with or without rHu-EPO (8.9 U/ml) for 15 minutes. In
general, cytoplasmic extracts contained more STAT-5 pro-
tein than nuclear extracts (Figure 7A). Nuclear extracts
showed moderate phosphorylation of STAT-5 which was
not affected by EPO. Cultured hepatocytes showed equal
levels of STAT-5 protein but also no increase in phospho-
rylated STAT-5 after treatment with rHu-EPO (10 U/ml for
15 minutes (Figure 7B) or 18 hours; data not shown).
Similar results were obtained for JAK-2: non-phosphor-
ylated JAK-2 was found in livers and hepatocytes irrespec-
tive of EPO treatment and changes in phosphorylation of
JAK-2 were not observed (Figure 8). Neither STAT-3 nor
pSTAT-3 levels in hepatocytes and the livers were altered
by rHu-EPO (data not shown).
For both STAT-5 and JAK-2, phosphorylation in UT-7 cells
served as positive controls for the activation of classical
EPOR downstream signalling: Withdrawal of rHu-EPO for
1 hour strongly reduced the phosphorylation of STAT-5
(Figure 7A and 7B) and JAK-2 (Figure 8A) while the sig-
nalling components were strongly phosphorylated upon
treatment with rHu-EPO (10 U/ml for 15 minutes).
Discussion
Hypoxic cell injury, hypoxia-reoxygenation injury and
cold-induced apoptosis to cultured hepatocytes are in
vitro models of injurious processes occurring to the hepa-
tocyte in vivo during warm or cold ischemia and upon
subsequent warm reperfusion of the liver. They cover a
wide range of injurious mechanisms from necrotic to
apoptotic cell injury [34,35]. Independent of the injurious
model used, however, rHu-EPO was without any protec-
tive effect in these in vitro models. Thus, there is a discrep-
ancy between the in vitro results obtained under
standardized conditions here and the known protection
provided by rHu-EPO against ischemia-reperfusion injury
to the liver in vivo [4-9].
We did not find any evidence for EPO-dependent signal-
ling either in the cultured hepatocytes or in the liver per-
fused in situ. RHu-EPO was not capable of activating JAK-
2, STAT-3 and STAT-5, i.e. decisive components of EPO-
mediated signal transduction, or of inducing Bcl-2, a well-
known effector molecule of EPO-mediated protection.
Only the measurements focusing directly on EPOR pro-
vided somewhat ambiguous results; although they as well
do not suggest the presence of a functional EPOR. On the
one hand, EPOR mRNA was detectable in the rat hepato-
cytes and perfused livers in line with data obtained from
the liver of neonatal pigs [42] but in contrast to a previous
study on mouse liver where no EPOR-specific PCR prod-
uct was detectable anymore after birth [43]. Interestingly,
while this manuscript was prepared Pinto et al. reported
EPOR activation in mouse hepatocytes which was blocked
by an anti-EPOR antibody [44]. Unfortunately, the
authors of that study performed no experiments to define
postreceptor signalling which makes a direct comparison
Effect of rHu-EPO on Bcl-2 expression Figure 6
Effect of rHu-EPO on Bcl-2 expression. Quantitative 
(RT-)PCR from total RNA was performed as described in 
Methods after a 30 hours incubation (18 h preincubation, 12 
h incubation) of hepatocytes with or without rHu-EPO (10 
U/ml) under normoxia or hypoxia (3% O2). Data obtained 
for hepatocytes from 6 separate animals are shown. Data 
represents means + S.D. *p < 0.05 vs. respective incubations 
at normoxia.
Table 1: Effects of high rHu-EPO concentrations on Bcl-2 mRNA 
levels in rat hepatocytes
Treatment Normoxia Hypoxia (3% O2)
Control 0.11 ± 0.03 fg/μl 0.05 ± 0.02 fg/μl
EPO 50 U/ml 0.09 ± 0.03 fg/μl 0.04 ± 0.01 fg/μl
EPO 100 U/ml 0.08 ± 0.03 fg/μl 0.04 ± 0.02 fg/μl
NOTE. Quantitative (RT-)PCR from total RNA was performed as 
described in Methods after a 24 hours incubation of cultured rat 
hepatocytes with or without high doses of rHu-EPO under normoxia 
or hypoxia (3% O2). Data are the means ± SD of 4 separate 
experiments with hepatocytes different animals each.BMC Gastroenterology 2009, 9:26 http://www.biomedcentral.com/1471-230X/9/26
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with this study difficult but it remains to be resolved
whether EPO preparations activate other signalling path-
ways than the classical JAK-2/STAT-5 cascade.
In our cells, EPOR mRNA expression was not stimulated
by exogenous EPO which contrasts to the behaviour of
other cell types such as erythroid progenitor cells, vascular
endothelial and neuronal cells [12,45-47]. EPOR protein
could unfortunately not be demonstrated, due to the una-
vailability of a specific antibody. However, clear evidence
for EPOR signal transduction pathways in the rat liver has
not been presented yet. Even for the in vivo experiments
on ischemia-reperfusion injury to the liver and on liver
regeneration following partial liver resection, where pro-
tection by rHu-EPO has been reported, no significant
downstream activation of STAT-3 or VEGF mRNA expres-
sion has been documented [8,10].
Effect of rHu-EPO on the phosphorylation of STAT-5 in rat  livers and hepatocytes Figure 7
Effect of rHu-EPO on the phosphorylation of STAT-5 
in rat livers and hepatocytes. Rat livers were perfused 
with 8.9 U rHU-EPO/ml and cultured hepatocytes incubated 
with 10 U/ml (both for 15 minutes). Afterwards, cytoplasmic 
and nuclear extracts were subjected to Western blotting. As 
a positive control for EPOR signalling whole cell extracts of 
the rHu-EPO-responsive cell line UT-7 were used that were 
treated with (or depleted from) rHU-EPO (10 U/ml for 15 
minutes). In (A) total STAT-5 and pSTAT-5 were determined 
for liver extracts. In (B) corresponding results are shown for 
rat hepatocytes. The blots represent results of 6 experi-
ments with different animals.
Effect of rHu-EPO on the phosphorylation of JAK-2 in rat liv- ers and hepatocytes Figure 8
Effect of rHu-EPO on the phosphorylation of JAK-2 in 
rat livers and hepatocytes. Rat livers were perfused with 
8.9 U rHU-EPO/ml and cultured hepatocytes incubated with 
10 U/ml (both for 15 minutes). Afterwards, cytoplasmic and 
nuclear extracts were subjected to Western blotting. As a 
positive control for EPOR signalling whole cell extracts of 
the rHu-EPO-responsive cell line UT-7 were used that were 
treated with (or depleted from) rHU-EPO (10 U/ml for 15 
minutes). Total JAK-2 and pJAK-2 were determined for 
extracts from (A) of perfused liver or (B) total cellular 
extracts from cultured hepatocytes. The blots represent 
results of 6 experiments with different animals.BMC Gastroenterology 2009, 9:26 http://www.biomedcentral.com/1471-230X/9/26
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Absence of protective EPO signalling fully explains the
absence of protection by rHu-EPO in the cultured hepato-
cytes. This, however, raises the question about the mecha-
nism of the liver protection by rHu-EPO in vivo and thus
about the underlying reason for the apparent discrepancy
between our in vitro and the published in vivo results.
Decisive pathophysiological mechanisms contributing to
the in vivo ischemia/reperfusion injury to the liver are
mediated or enhanced by endothelial and Kupffer cells,
i.e. by liver cells other than hepatocytes [35,48]. RHu-EPO
may directly or indirectly act on these cells and thus influ-
ence the injurious response. Further, systemic effects of
rHu-EPO on the cardiovascular, respiratory and neuronal
system may modulate the outcome of ischemia/reper-
fusion injury to the liver in vivo. Other known indirect
effects of rHu-EPO that may play a role are the suppres-
sion of the inflammatory response via down-regulation of
NF-κ and AP-1 [49] and promotion of liver regeneration
via stimulation of haematopoietic cells located in the liver
[10]. In line with this, Yilmaz et al. [4] reported that „It
may be that EPO acts upon the liver via mechanisms other
than the tyrosine kinase pathway, i.e. that the protective
effects of EPO on liver and nerves operate via different
mechanisms."
Another or additional explanation for the in vivo liver
protection by commercial rHu-EPO preparations is the
high glycine concentration of the stock solutions. Unfor-
tunately, no controls with heat-inactivated rHu-EPO have
been performed in the in vivo studies. Assuming that a
stock solution containing 10,000 U rHu-EPO and 5 mg
glycine/ml was used, the application of 1,000–5,000 U/kg
body weight, as performed in vivo, would increase the gly-
cine blood concentration from around 180 μM [50] to
280–690 μM; given a blood volume of 65 ml/kg rat and
provided that there is no glycine uptake by tissue (which
of course does occur). Even higher glycine concentrations
would be reached when stock solutions containing less
rHu-EPO were used since their glycine content is always
maintained at 5 mg/ml. Which stock solutions have been
used is not clearly given in the in vivo studies cited above.
Nevertheless, already ≥ 66 μM glycine significantly pro-
tected isolated hepatocytes form hypoxia/reoxygenation
injury in the present study and slightly more (100 μM) in
a previous one [36].
Conclusion
In conclusion, we demonstrated that rHu-EPO has no
protective effect on hypoxic injury, hypoxia-reoxygena-
tion injury and cold-induced apoptosis to isolated cul-
tured rat hepatocytes. This is in line with the absence of a
protective EPO-dependent signalling in these cells as well
as in the rat liver perfused in situ with rHu-EPO. We sug-
gest that the protection provided by rHu-EPO in vivo
against ischemia-reperfusion and other causes of liver
injury does not result from a direct effect on hepatocytes.
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